FDA approves Novo Nordisk’s Victoza for heart disease treatment in type 2 diabetes patients
Novo Nordisk diabetes drug Victoza (liraglutide) has been approved by the US FDA for treating major cardiovascular diseases associated with type 2 diabetes.
In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use its diabetes drug Victoza (liraglutide) for treating heart diseases associated with type 2 diabetes. This approval marks a pivotal expansion of Victoza’s usage, positioning it as a key player in […]